Walgreens Boots Alliance, Inc. (W8AD.XC)
| Previous close | 16.47 |
| Open | 16.59 |
| Bid | 16.29 x 0 |
| Ask | 16.33 x 0 |
| Day's range | 16.47 - 16.47 |
| 52-week range | 16.47 - 32.28 |
| Volume | |
| Avg. volume | 13 |
| Market cap | 14.207B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.56 |
| Earnings date | 25 Jun 2024 - 01 Jul 2024 |
| Forward dividend & yield | 0.93 (5.68%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
Yahoo FinanceWalgreens partners with Boehringer Ingelheim for clinical trials
Walgreens is ramping up its clinical trial offerings with Big Pharma players.
Business WireWalgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
DEERFIELD, Ill. & RIDGEFIELD, Conn., May 02, 2024--Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and r
BenzingaInvestor Optimism Dampens as Walgreens Boots Alliance Struggles With Market Turbulence
Walgreens Boots Alliance Inc. (NASDAQ:WBA) is facing tumultuous times as it grapples with a challenging turnaround, leading to a drastic decline in its stock value, marking its worst performance in over five years. The company’s shares plummeted by 18% in April, nearing a 26-year low, following a downward revision of its outlook. This revision was accompanied by concerns over decreased consumer spending and the revelation of a substantial unpaid tax liability amounting to $2.7 billion, adding to
